GSK expands late-stage clinical trials with $2.52 billion cost-saving program

1. 1GSK announced a roughly $2.52 billion cost-saving program primarily aimed at securing funding for late-stage clinical development
2. 2The company will increase late-stage trials from about 10 to more than 20 by 2026, covering 7 assets and 18 indications
3. 3With second-quarter results exceeding expectations, the move expands research before the 2028 patent expiration of HIV component dolutegravir

Source Quartz +1 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →